At the end of Q2, the biotech has a cash balance of $808 million and burned $95 million in the 1H of the year. Viking ...

Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $23.94, demonstrating a +1.44% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a ...

Viking Therapeutics, Inc.'s VK2735 oral trial met efficacy and safety endpoints, but high discontinuation rates and modest weight loss disappointed Wall Street, triggering a steep sell-off. Despite ...

Viking Therapeutics presents a high-risk, high-reward opportunity in the exploding GLP-1 weight loss market, where early clinical data for its VK2735 drug shows competitive results against current ...

Viking Therapeutics (NASDAQ: VKTX) suffered a brutal market sell-off on Tuesday, with shares plunging over 40% in one of the biotech firm's steepest single-day drops since its initial public offering ...

Viking Therapeutics is working on an injectable weight loss drug candidate and one in pill format. The biotech might eventually compete against pharma giants Eli Lilly and Novo Nordisk. Early last ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, achieving only 12.4% weight loss. Viking Therapeutics' dual-formulation obesity ...

Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:VKTX). And retail traders should know. We noticed this today when the positions showed up on publicly ...